A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Anastrozole (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 05 Jun 2018 Trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.